* HOOKIPA Pharma Inc reported a quarterly adjusted loss of $1.10​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.70. The mean expectation of three analysts for the quarter was for a loss of $1.28 per share. Wall Street expected results to range from $-1.65 to -91 cents per share.

* Revenue fell 31.5% to $4.70 million from a year ago; analysts expected $6.25 million.

* HOOKIPA Pharma Inc's reported EPS for the quarter was a loss of $1.10​.

* The company reported a quarterly loss of $13.84 million.

* HOOKIPA Pharma Inc shares had fallen by 27.0% this quarter and lost 61.2% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 0.1% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for HOOKIPA Pharma Inc is 48.00 This summary was machine generated from LSEG data November 15 at 02:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -1.28 -1.10 Beat

Jun. 30 2024 -1.25 -1.52 Missed

Mar. 31 2024 -1.02 1.10 Beat

Dec. 31 2023 -1.93 -2.20 Missed